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Background: Methylphenidate (MPH) is the most common drug treatment of attention deficit / hyperactivity
disorder (ADHD) in children. Treatment with MPH is contraindicated in the presence of certain psychiatric, cerebro-
and cardiovascular conditions. We assessed MPH treatment prevalence and incidence and the frequency of
comorbid conditions related to these contraindications in new MPH users compared to a control group without
ADHD and ADHD medication.
Methods: We used health care data for the years 2004 to 2006 from the German Pharmacoepidemiological
Research Database (GePaRD) which includes about 18% of the German population. MPH treatment prevalence and
incidence was assessed based on at least one MPH prescription in the given year. In MPH users, the prevalence of
psychiatric and other comorbidities was assessed in the quarter of the first MPH prescription and the three
preceding quarters, whereas in controls it was assessed in the earliest four quarters of continuous insurance time
starting at 01.01.2004 or the start of insurance if this was later. Differences in the presence of comorbid diagnoses
between MPH users and controls were tested by logistic regression.
Results: In 2005, 1.5% of all children and adolescents aged 3 to 17 years (2.3% of males and 0.6% of females)
received MPH in Germany. The proportion of children with a record of a psychiatric comorbidity in any of the nine
ICD categories of diagnoses was substantially higher in new MPH users (83%) compared to controls (20%). Cerebro-
and cardiovascular comorbidities were rare in general. Still, among new MPH users, 2% of males and females had a
diagnosis of a pre-existing cardiovascular disorder but only 1.2% of controls.
Conclusions: Besides MPH treatment prevalence we first publish age-specific incidence rates for Germany. A high
proportion of children who were started on MPH had a record of a psychiatric comorbidity preceding the first
prescription. Cerebro- and cardiovascular conditions were rare in the studied age range, but still higher among
children who received MPH than in the control group. Results show that in a substantial subgroup of patients,
comorbidities require a thorough weighting of possible risks of MPH medication against the risks of untreated
ADHD.Background
The stimulant methylphenidate (MPH) is the most com-
mon drug treatment for attention-deficit/hyperactivity
disorder (ADHD) in children and adolescents [1,2].
MPH is licensed in Germany for the treatment of
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reproduction in any medium, provided the orthe very rare sleep disorder narcolepsy without any age
restriction [3]. In Germany, MPH was launched in 1954
and there was a substantial increase in the volume of
prescriptions over the last two decades. Between 1990
and 2009, the number of prescribed daily doses of MPH
has multiplied by a factor of 184 [4,5]. While MPH treat-
ment prevalence based on health care data was reported
for different age groups, years and countries [2,6-10],
treatment incidence was reported less often [11-13].
Drug safety of stimulants has been studied extensively
[14-16]. Published case reports of adverse cardiovascular
events in persons taking stimulant medication [17], andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pressure and heart rate [16,18,19], have led to public
health and regulatory concerns regarding the cerebro-
and cardiovascular safety [20]. While cardio- and cere-
brovascular conditions are generally rare in childhood, it
is well established that psychiatric comorbidity is consid-
erable in children diagnosed with ADHD [21,22].
A safety evaluation of MPH-containing medicines
requested by the European Commission and conducted
by the European Medicines Agency (EMA) has resulted
in a revised list of contraindications which, amongst
others, includes pre-existing cerebrovascular, cardiovas-
cular and psychiatric conditions, glaucoma, phaeochro-
mocytoma and hyperthyroidism [23,24]. This safety
evaluation has led to a Europe-wide standardisation of
the information contained in the Summary of Product
Characteristics (SPC) for MPH-containing products,
which were implemented in Germany by mid-2009. The
investigation of the prevalence of co-morbid conditions
newly contraindicated in ADHD children who receive
MPH provides an estimation of the magnitude of pos-
sibly affected children by the EMA safety evaluation.
The aim of the current study was to assess the preva-
lence and incidence of MPH prescribing and the extent
of pre-existing comorbidity at the time of the first MPH
prescription in comparison to a control group without
MPH and without ADHD preceding the EMA referral.
The specific aims were: 1) to estimate MPH treatment
prevalence and incidence in children and adolescents
aged 3 to 17 years in Germany 2) to compare the preva-
lence of psychiatric and other relevant comorbidities in
MPH users with a control group.
Methods
Data source
This study was based on data from the German Pharma-
coepidemiological Research Database (GePaRD) [25].
GePaRD consists of records of four statutory health
insurance companies (SHIs) and comprises data of more
than 15 million insurance members of all ages (approxi-
mately 18% of the German population). The database
covers all regions of Germany and includes demographic
information and information on hospitalisations, out-
patient care and outpatient prescriptions. All diagnoses
are coded according to the German Modification of the
International Classification of Diseases, 10th Revision
(ICD-10-GM). Outpatient diagnoses are accompanied by
an indicator for their diagnostic certainty with the speci-
fications ‘certain’, ‘history of ’, ‘suspicion of ’ and ‘exclusion
of ’. Outpatient diagnoses can only be allocated to a
quarter of the year, since outpatient physician visits are
reimbursed quarterly. Statutory health insurance is
mandatory in Germany except for persons above a rela-
tively high income threshold who are permitted tochoose private health insurance instead. However, also
persons above the income threshold can choose to re-
main in statutory health insurance as it provides free
membership for family members without an income of
their own. In total, about 90% of the German population
is insured in one of several statutory health insurance
companies. Preliminary analyses regarding the age and
sex distribution, the number of hospital admissions and
drug use have shown the database to be adequately rep-
resentative of information published in official statistics
[25]. The current study was based on data for the years
2004 to 2006, since more recent data were not available
for all four SHIs at the time of the analysis.
In Germany, the use of health insurance data for sci-
entific research is regulated by the Code of Social Law
(SGB X). Approval for the use of the data for this project
was granted by all SHIs that contributed data, the Fed-
eral Ministry of Health, and the Senate of the Federal
State of Bremen. No informed consent was required as
the analysis is based on routinely collected, pseudony-
mised data. The data is not publicly available but
other institutions could apply for the data to the re-
spective SHIs.
Study design and measures
For the inclusion of a child into the study, the follow-
ing three conditions had to be satisfied: (1) valid in-
formation on year of birth and sex; (2) age between 3
and 17 years in the respective year; (3) residence in
Germany. Sex- and age-specific MPH treatment
prevalence and incidence were calculated for 2005
and 2006. All MPH prescriptions were identified
using the anatomic-therapeutic-chemical (ATC) classi-
fication code N06BA04.
Assessment of MPH treatment prevalence
For the assessment of MPH treatment prevalence, all
insurees who were insured at least one day in the
respective study year were included. The number of
insurees for whom at least one MPH prescription was
filled in the respective year was divided by all insurees
ever insured during that year.
Assessment of MPH treatment incidence
We included those persons in the analysis who were
continuously insured for at least 366 days between
01.01.2004 and 31.12.2006 and did not have an MPH
prescription in the first 12 months of their insurance
period. Incident MPH users were those who had at least
one MPH prescription in 2005 or 2006. We determined
MPH treatment incidence as cumulative incidence by
dividing the number of incident MPH users by the total
number of insured persons stratified by age and sex for
the years 2005 and 2006.
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For the assessment of differences in comorbidity, we
compared comorbid disorders in incident MPH users
with those of a control group. In MPH users, we
assessed comorbidity in the quarter of the first MPH
prescription and the three preceding quarters. As con-
trol group we selected insurees who did not fill a pre-
scription for MPH or atomoxetine and who had no
diagnosis of hyperkinetic disorders (ICD-10-GM code
F90) during the entire study period. Comorbidity in the
control group was assessed in the earliest four quarters
of continuous insurance time starting at 01.01.2004 or
the start of insurance if this was later.
For the analysis of comorbidities we included hos-
pital and outpatient diagnoses, but excluded out-
patient diagnoses recorded as ‘exclusion of ’, ‘sus
picion of ’ or ‘history of ’. The assessment of psychi-
atric comorbidity included all ICD-10-GM codes for
mental and behavioural disorders apart from the
codes F00-F09 which refer to dementia and other or-
ganic mental disorders. Psychiatric comorbidities
were stratified according to the upper-level groups of
the ICD-10 classification scheme (F10-F19, F20-F29,
F30-F39, F40-F48, F50-F59, F60-F69, F70-F79, F80-89,
F91-F98, and F99). Of these, the frequency of the
psychiatric disorders bipolar affective disorder (F31),
depression including depressive episode and recurrent
depressive disorder (F32 and F33), generalized anxiety
disorder (F41.1), conduct disorder (F91) and oppos-
itional defiant disorder (F91.3) was determined indi-
vidually. Further, comorbid conditions which were listed
as contraindications by the European Medicines Agency
(EMA) were assessed [23]. A full list of ICD-10-GM codes
included for the assessment of comorbidity is available
on request.Statistical analysis
For the MPH treatment prevalence and incidence
estimates 95% confidence intervals (95% CI) were
calculated following the method recommended by
Newcombe and Altman [26]. To obtain representa-
tive prevalence and incidence estimates for the Ger-
man population, sex- and age-specific estimates were
weighted by corresponding population weights for
Germany, derived from the German Federal Statis-
tical Office [27]. Logistic regression adjusting for age
as categorical variable in one-year age groups was
used to calculate p-values for differences in the pres-
ence of comorbid diagnoses between users and the
control group. P-values of 0.05 or smaller were
regarded statistically significant. All statistical ana-
lyses were conducted using the statistical program
package SAS version 8.2.Results
MPH treatment prevalence and incidence
In total, 2,150,362 insurees aged 3 to 17 years were
included for the estimation of MPH treatment preva-
lence and about the same number of children
(N=2,089,877) for the estimation of MPH treatment in-
cidence. The overall treatment prevalence for the 3- to
17-year-old population of Germany was 14.7 per 1,000
insurees in 2005 and 16.9 per 1,000 insurees for 2006
and was about four times higher for males than for
females (Table 1).
When treatment prevalence was further stratified by
age, boys showed a marked increase from the age of 6
with a peak prevalence at age 11, followed by a steep de-
crease from the age of 13 years. For girls, the population
receiving MPH increased from the age of 6 to a max-
imum at the age of 10 and slightly decreased thereafter.
For males, the peak prevalence at age 11 was 44.8 and
49.9 per 1,000 insurees in 2005 and 2006, respectively.
For girls, the peak prevalence at age 10 was 11.5 per
1000 insurees in 2005 and 13.4 per 1,000 insurees in
2006. The treatment prevalence was somewhat higher
in 2006 than in 2005, which was more marked for
males (Figure 1).
The initiation of MPH treatment stratified by age and
sex revealed a similar picture. For boys, the incidence of
MPH treatment was 6.7 per 1,000 male insurees for
2005 (7.2 per 1,000 insurees for 2006) and 1.9 per 1,000
female insurees in 2005 (2.2 per 1,000 insurees for
2006). The MPH treatment incidence peaked at age 9
for both sexes (Figure 2). Differences between the two
years were more marked for boys than for girls.
Comorbidity
Overall, psychiatric comorbidity was statistically signifi-
cantly higher in incident users of MPH than in controls
for all included diagnostic groups, including the very
rare disorders ‘mental and behavioural disorders due to
psychoactive substance use’, ‘schizophrenia, schizotypal
and delusional disorders’ and ‘unspecified mental disor-
ders’. About half of all incident MPH users had a diag-
nosis of disorders of psychological development and also
about one half had a diagnosis of ‘Behavioral and emo-
tional disorders with onset usually occurring in child-
hood and adolescence’. ‘Neurotic, stress related and
somatoform disorders’ were the third most common
psychiatric comorbidity in MPH users, followed by the
specific category ‘conduct disorder’. Diagnoses of the
other specific psychiatric comorbidities ‘bipolar affective
disorder’, ‘depression’, and ‘oppositional defiant disorder’
were present in less than four percent of MPH users and
in about one percent or less of controls (Table 2).
The physical comorbidities included in this analysis
were quite rare, with most of them present in less than
Table 1 Prevalence and incidence of methylphenidate treatment per 1,000 children and adolescents aged 3 to
17 years in 2005 and 2006
Year Male (95% CI) Female (95% CI) Total (95% CI)
Treatment prevalence1 2005 23.35 (23.05-23.65) 5.50 (5.35-5.65) 14.66 (14.49-14.83)
2006 26.70 (26.38-27.02) 6.59 (6.43-6.75) 16.90 (16.72-17.09)
Treatment incidence1 2005 6.65 (6.48-6.81) 1.87 (1.78-1.96) 4.32 (4.23-4.41)
2006 7.20 (7.03-7.37) 2.16 (2.07-2.26) 4.75 (4.65-4.84)
1 Weighted for the German population aged 3 to 17 years in the respective year, taking age and federal state into account.
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mon physical comorbidities were pre-existing cardiovas-
cular disorders, followed by hyperthyroidism and
haemodynamically significant heart disease and were sta-
tistically significantly more common in incident MPH
users compared to controls. Most other cardiovascular
comorbidities showed no differences between MPH
users and controls. The prevalence of glaucoma was
similar in both groups. No diagnoses of cerebral aneur-
ism or pheochromocytoma could be identified in our
study (Table 3).
Discussion
With this study, we complement previous studies based
on health care data and provide prevalence and inci-
dence of MPH treatment in children and adolescents in
Germany using a large health care database. Our study
showed that the prevalence of psychiatric comorbidities
is considerably higher in MPH users compared to con-
trols, whereas the differences for physical comorbidities
were less pronounced.
MPH treatment prevalence
For Germany, MPH treatment prevalence was reported
in two regional [2,8] and one national study [6], each
























Male 2005 Female 2005
Figure 1 Prevalence of MPH prescriptions per 1,000 children and ado
represent 95% confidence intervals.Our findings which are based on data from four health
insurance companies covering all parts of Germany are in
accordance with those of the national study [6], which
reported a treatment prevalence of 1.7% overall and of
2.7% for males and of 0.7% for females in children aged 0
to 17 years in 2006. Another study based on data from the
Federal State Mecklenburg-West Pomerania reported a
total MPH treatment prevalence of 1.4% in 0- to 15-year-
old children in 2001 [8]. A lower MPH treatment preva-
lence of 1.1% was also reported from Hesse in 2007,
with an estimate of 1.7% for boys and 0.4% for girls
under the age of 18 [2]. These lower prevalence esti-
mates in Mecklenburg-West Pomerania and Hesse
may indicate regional variations in MPH treatment in
Germany [8]. In our study, treatment prevalence
increased steadily from age 6 to age 11, which was
also observed in the study from Hesse [2]. Males had
a four times higher treatment prevalence than females
which equates to their about fourfold higher preva-
lence of ADHD diagnosis [28].
MPH treatment incidence
Treatment incidence overall was 4.75 per 1000 children
and adolescents in 2006 and was 3.3-fold higher in male
than in female children. No comparable estimates for
MPH treatment incidence have been reported for10 11 12 13 14 15 16 17
years)
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Figure 2 Incidence of MPH prescriptions per 1,000 children and adolescents by age and sex in 2005 and 2006. Note: Indicators represent
95% confidence intervals.
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scription data of children aged 0 to 17 years found an in-
cidence of 5.4 per 1,000 children for stimulants and
atomoxetine combined for the year 2006 which was 2.5
times higher in boys than in girls [10]. A study from the
United States (US) based on Medicaid data reported thatTable 2 Frequency of psychiatric comorbidities in incident me




Mental and behavioural disorders (F10-F99)2 82.52
Mental and behavioural disorders due to psychoactive
substance use (F10-F19)
0.81
Schizophrenia, schizotypal and delusional disorders
(F20-F29)
0.35
Mood [affective] disorders (F30-F39) 3.87
Bipolar affective disorder (F31) 0.01
Depression (F32, F33) 2.54
Neurotic, stress-related and somatoform disorders
(F40-F48)
19.81
Generalized anxiety disorder (F41.1) 0.57
Behavioural syndromes associated with physiological
disturbances and physical factors (F50–F59)
5.04
Disorders of adult personality and behaviour (F60-F69) 10.36
Mental retardation (F70-F79) 3.80
Disorders of psychological development (F80-F89) 52.25
Behavioural and emotional disorders with onset usually
occurring in childhood and adolescence2 (F91-F98)
55.94
Conduct disorder (F91) 14.78
Oppositional defiant disorder (F91.3) 3.65
Unspecified mental disorder (F99) 1.11
1 Percentages add up to more than 100% since insurees could have more than one
2 Codes for hyperkinetic disorders (F90.x) were excluded from this group.
3 The percentage of male controls with a respective diagnosis was 0.004 (N=41).8.9 per 1,000 children and youths below the age of
twenty were newly started on any ADHD drug in 2003
to 2004 [13]. This might indicate a different prescribing
behaviour in the US. Another study from the
Netherlands which was based on a sample of pharmacy




Incident users Controls P-
value(N=978,790)%1 (N=3,837)%1 (N=1,000,300)%1
21.53 <0.01 82.28 18.64 <0.01
0.30 <0.01 1.15 0.34 <0.01
0.06 <0.01 0.47 0.07 <0.01
0.48 <0.01 5.40 0.69 <0.01
0.003 0.03 0.08 0.01 <0.01
0.33 <0.01 3.62 0.55 <0.01
3.58 <0.01 25.70 4.88 <0.01
0.18 <0.01 1.09 0.23 <0.01
1.18 <0.01 6.18 1.49 <0.01
1.11 <0.01 9.59 1.11 <0.01
0.58 <0.01 5.08 0.44 <0.01
13.87 <0.01 48.45 9.90 <0.01
6.03 <0.01 54.29 4.38 <0.01
1.15 <0.01 11.02 0.81 <0.01
0.18 <0.01 3.08 0.11 <0.01
0.20 <0.01 1.59 0.26 <0.01
type of comorbidity.
Table 3 Selected physical comorbidities in incident methylphenidate users and controls in 2005 to 2006
Male Female
Diagnostic Group Incident users Controls P-value Incident users Controls P-value
(N=13,460)%1 (N=978,790)%1 (N=3,837)%1 (N=1,000,300)%1
Pre-existing cardiovascular disorders 2.00 1.24 <0.01 2.06 1.18 <0.01
Angina pectoris 0.13 0.19 0.34 0.16 0.18 0.90
Arterial occlusive disease 0.01 0.02 0.98 0.08 0.03 0.04
Potentially life threatening arrhythmias 0.51 0.17 <0.01 0.57 0.14 <0.01
Cardiomyopathy 0.10 0.05 0.02 0.03 0.05 0.57
Severe congenital heart disease 1.23 0.78 <0.01 1.20 0.75 <0.01
Heart failure 0.09 0.05 0.02 0.03 0.05 0.69
Myocardial infarction 0.01 0.01 0.64 0.03 0.02 0.43
Severe hypertension 0.07 0.05 0.34 0.05 0.05 0.82
Pre-existing cerebrovascular disorders 0.19 0.11 <0.01 0.13 0.10 0.36
Stroke 0.10 0.05 0.02 0.10 0.04 0.02
Glaucoma 0.39 0.33 0.34 0.34 0.35 0.96
Hyperthyroidism 1.22 0.15 <0.01 0.89 0.27 <0.01
1 Percentages could add up to more than 100% since insurees could have more than one type of comorbidity.
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age of 44 years for 2006 [12]. Since this estimate also
included adults, it is not surprising that it is lower than
our estimate for children only. In our study the MPH
treatment incidence increased markedly from the age of
6, the typical age of starting school in Germany, up to
the age of 9 years. Similarly, the study from the
Netherlands [12] found the MPH treatment incidence to
be highest in the 6- to 11-year-old population, compared
to the age groups below 6 years of age and 12 to 17 years.
No age-specific incidence rates were reported for
Germany prior to our study.
Psychiatric comorbidities
According to the EMA, the presence of a diagnosis or
history of severe depression, anorexia nervosa/anorexic
disorders, suicidal tendencies, psychotic symptoms, se-
vere mood disorders, mania, schizophrenia, psycho-
pathic/borderline personality disorder, and severe
episodic (Type I) bipolar affective disorder are contrain-
dications for the use of MPH [23]. Overall, all investi-
gated psychiatric comorbidities were with 82% very
common in children with MPH prescriptions and their
overall frequency did not differ between boys and girls.
The frequent co-occurrence of ADHD with psychiatric
conditions is well known [21,29-31] and was shown in
both, epidemiologic [32,33] and clinical studies [21,34-36].
Psychiatric conditions are so frequent and interwoven
with ADHD symptoms that the introduction of new
ADHD subtypes based on patterns of psychiatric comor-
bidity has been proposed [22,37]. A Swedish community-
based study of 7-year-old school children found a similarpsychiatric comorbidity prevalence (87%) for children
who, according to a clinical examination and parent and
teacher interviews, fulfilled the criteria of the Diagnostic
and Statistical Manual of Mental Disorders (DSM-III-R)
for ADHD [33].
Generally, studies reporting psychiatric comorbidity in
children with ADHD are mainly based on clinical exami-
nations of small patient samples [29,38]. In these studies,
children are actively screened for psychiatric comorbid
conditions which results in a very high proportion of
ADHD children with these comorbidities. Due to these
methodological differences, the published estimates are not
comparable to ours. An interesting point is, that ADHD
diagnoses in our study were defined by ICD-10-GM
criteria, which in contrast to the DSM classification
demand that the diagnosis ADHD should not be given in
the presence of mood disorders, anxiety disorders, schizo-
phrenia or pervasive developmental disorders.
Conduct disorder was the most prevalent specific
comorbidity in our study. This accords with a European
clinical guideline on ADHD which states that oppositional
defiant disorder (ODD) and conduct disorder (CD) are
very common in ADHD and could rather be seen as a
complication of ADHD than a comorbidity [39]. For
Germany, the Attention-deficit/hyperactivity Disorder
Observational Research in Europe (ADORE) study has
found ODD and/or CD in 46% (n=197) of 6- to 18-year-
old patients with ADHD symptoms who had not formally
been diagnosed with ADHD before study inclusion
[40,41]. The German part of this study included 434
children with ADHD symptoms and was based on stan-
dardised physician and parent reported measures in all
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found in the ADORE study compared to our results.
In another small population-based sample of 7-year-old
children as many as 60% of those with ADHD had a
comorbid diagnosis of ODD [33]. A detailed discussion of
the association of conduct disorder with ADHD can be
found in a review by Biederman and colleagues, which
reports that ODD/CD have been found in 30% to 50% of
children with ADHD in clinical and in epidemiological
studies [21].
A prospective study showed that children with ADHD
are at a 4.3-fold higher risk to develop major depression
or dysthymia (according to DSM-IV criteria) through the
age of 18 compared to children without ADHD [42].
Another prospective study including adolescent and
young adult females with ADHD also using DSM-IV cri-
teria found a 2.5 times higher risk of major depression
in the presence of ADHD compared to female controls
without ADHD [29]. Due to non-specific coding of de-
pression in the database (F32.9), we could not investigate
major depression in children with and without MPH
use, however, depression overall was significantly more
frequent in male and female children receiving MPH
prescriptions than in the respective controls.
Clinical and epidemiological studies have reported that
ADHD and anxiety disorders occur together in 8% to
30% of children [31]. A recent review stated that the co-
occurrence of anxiety disorders with ADHD averages
25% in these studies [43]. The ADORE study found anx-
iety and/or depression in 14% (n=57) of German study
participants [41]. Anxiety disorders in a wider sense also
include obsessive compulsive disorders and a variety of
other forms of anxiety disorders. In our study, only gen-
eralized anxiety disorders were analysed and occurred
rarely, but, as all considered psychiatric comorbidities
was significantly more frequent in MPH users compared
to controls.
We found only a small number of children and adoles-
cents with a diagnosis of bipolar affective disorder in our
study, but still there were statistically significant differ-
ences between MPH users and controls. In the literature,
bipolar disorder was reported in up to 22% of children
with ADHD [43]. The difference can be related to the
fact that ICD-10-GM criteria demand that the diagnosis
ADHD should not be given in the presence of mood dis-
orders, anxiety disorders, schizophrenia or pervasive de-
velopmental disorders.
Cardiovascular and other comorbidities
A review of adverse drug reaction reports in the US and
Europe has led to concerns that MPH treatment may be
associated with rare cardiovascular complications [17].
The EMA contraindicated the use of MPH in patients
with the following cardiovascular conditions: pre-existing cardiovascular disorders including heart failure,
arterial occlusive disease, angina, haemodynamically sig-
nificant congenital heart disease, cardiomyopathies,
myocardial infarction, potentially life-threatening
arrhythmias and channelopathies [23]. Meanwhile, two
database studies investigating the cardiovascular safety
of ADHD drugs have been published which did not
show an increased risk for serious cardiovascular out-
comes [44,45]. Further contraindications resulting from
the EMA safety evaluation are cerebrovascular disorders,
phaeochromocytoma, hyperthyroidism or thyrotoxicosis,
and glaucoma. A thorough pre-treatment and ongoing
screening of the psychiatric and cardiovascular status of
the patient is considered necessary by the EMA.
Even though cardiovascular conditions are quite rare
in children in general, we found higher prevalence esti-
mates for pre-existing cardiovascular disorders in chil-
dren who were started on MPH treatment compared to
controls, especially for congenital heart diseases and life-
threatening arrhythmias. There is some evidence for
ADHD being more prevalent in children with heart dis-
ease than in the general paediatric population consistent
with our findings [46]. A possible explanation for this
association is that chronic or intermittent hypoxia has
an adverse impact on development, behaviour and aca-
demic achievement [47].
Our prevalence estimates of congenital heart disease
in controls were somewhat higher than those from a
Canadian population-based database study which
reported a prevalence of severe congenital heart disease
of 0.02 per 100 children and adolescents under the age
of 18 years in 2000 [48]. Since no specific estimates for
the prevalence of the investigated cardiovascular and
other comorbidities in children are published for
Germany, it was not possible to compare our estimates
of the prevalence of these disorders in the control group
with national estimates.
ADHD has been associated with a generalized resist-
ance to thyroid hormone, but this could not be con-
firmed in clinical studies [49,50]. It is not clear why
hyperthyroidism was more common in MPH users in
our study. A possible explanation could be given by
more frequently performed diagnostic investigations for
hyperthyroidism in children with ADHD and, as a
consequence, a more frequent detection of clinically
non-severe cases.
Strengths and limitations
The main strengths of this analysis are the large size and
the population-based nature of the database. GePaRD
consists of records of four statutory health insurance
companies and was shown to be representative for
Germany regarding the sex and age distribution,
hospital admissions and drug prescriptions [25,51].
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sons included in the database across federal states,
we weighted the derived estimates with population
weights obtained from the Federal Statistical Office
[27]. In Germany, MPH belongs to the controlled
substances and prescribing is regulated by law. Thus,
MPH prescriptions are considered to have a high
validity and are easily identifiable in GePaRD.
Our study focussed on description of pre-existing
comorbidities among children receiving MPH to investi-
gate the impact of new contraindications implemented
by the EMA. MPH is mainly used for the treatment of
ADHD and the only other indication it is licensed for in
Europe is the very rare condition narcolepsy. Since
under-coding of ADHD diagnosis in routine data may
occur, we equated children who received MPH treat-
ment with children with ADHD. This might have lead to
some misclassification. Among children with ADHD
diagnoses, the presence of certain psychiatric comorbid-
ities decreased the probability of drug prescriptions in
two US-based studies using Medicaid data [52,53]. This
might indicate that comorbidity is less prevalent in
MPH-treated patients than in ADHD patients overall,
however, we do not know whether these results are
transferable to Germany. The higher psychiatric comor-
bidity in Germany found in the ADORE study, which
was based on an investigation of children with ADHD
symptoms overall and not only of those treated with
MPH, could indicate that this may also apply to
Germany.
Due to diagnostic coding by ICD-10-GM codes in the
database, we could only assess diagnoses which are
coded in this system. Some contraindications for MPH,
e.g. potentially life-threatening channelopathies, could
not be assessed as they do not have separate codes in
the ICD-10 coding system. Also, ICD-10 codes do not
give any indication of the severity of the disease. Some
psychiatric diagnoses may be under coded as e.g. ODD,
explaining the lower prevalence found in our study than
in other German studies.
ADHD children are likely under closer surveillance
than control children and may additionally be screened
for organic causes of their symptoms. For this reason,
some bias regarding the detection of comorbidity in
ADHD children is possible. Additional analyses (i) of all
newly diagnosed ADHD patients and (ii) of all newly
diagnosed ADHD patients who started treatment with
MPH within 365 days of their ADHD diagnosis in the
database showed only slight differences in the prevalence
of comorbidities compared to the MPH users in this
study. These additional analyses were conducted in chil-
dren within the same age range as in this study, thereby
ruling out possible concerns regarding detection bias in
ADHD children as far as possible. Only hyperthyroidismwas substantially higher in ADHD children in this study
compared to newly diagnosed ADHD children. This
might be in fact the result of detection bias as discussed
earlier.
Finally, at the time the analysis was conducted, only
data for the years 2004 to 2006 were available. For that
reason, we were not able to ascertain the impact of the
contraindications introduced by the EMA in the begin-
ning of 2009 on prescribing behaviour. Our study pro-
vides insight in how many children might be affected by
psychiatric comorbidity in general and by these newly
agreed contraindications in particular. MPH treatment
of ADHD in children with contraindications might
outweigh the risks of not treating ADHD in many
cases [18,54].
Conclusions
MPH treatment prevalence was in accordance with the
published estimate of a national study, while results
from smaller regional studies may indicate regional var-
iations in prescribing behaviour. In this study we
reported age-specific treatment incidence rates for the
first time. Children starting MPH treatment had a high
prevalence of pre-existing psychiatric comorbidities
which may affect MPH prescribing. Cardiovascular and
other comorbidities were generally rare, but require
attention as they were more common among those who
received MPH than in the control group.
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